RBD-7022

N/A

Report date: 2026/05/25 20:02:40
NME

Base Information

Drug NameRBD-7022
Drug Alias NameRBD7022RBD-7022SR043SR-043QLC-7401
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionProprotein convertase subtilisin kexin type 9 inhibitors
TargetsProprotein convertase subtilisin kexin type 9
Therapy Area/IndicationsSitosterolemiaHypercholesterolemiaHyperlipidemias +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesSuzhou Ribo Life Science Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesQilu Pharmaceutical Co LtdSuzhou Ribo Life Science Co Ltd
Inactive CompaniesN/A
Active IndicationsSitosterolemiaHypercholesterolemiaHyperlipidemias +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A